Please login to the form below
Deal Watch table for October 2014
Table listing all the major pharma mergers, acquisitions and collaborations in the past month
This table lists all the major pharma collaborations, acquisitions and mergers agreed during October 2014.
For an indepth analysis of these deals, read 'Pharma deals during October 2014'
| Licensor acquired / licensee acquirer | Deal type | Product / technology | Headline ($m) |
| Becton Dickinson/CareFusion | Company acquisition | Medical equipment builds US sales base | 12,200 |
| Auxilium/Endo | Company acquisition | Urology and orthopaedic products including alprostadil for ED | 2,600 |
| NewLink Genetics/Genentech | Collaboration and licence | For development of NLG919 and next generation IDO pathway inhibitors | 1,150 |
| Sutro Biopharma/Celgene | Licence plus option to acquire Sutro | For development of multispecific antibodies and antibody drug conjugates (ADCs) | 1,000 |
| Aduro BioTech/J&J | Expansion of collaboration | Lung cancer immunotherapies including ADU 214 | 847 |
| Lineage Therapeutics/Impax Laboratories | Company acquisition | Includes generic and branded products such albendazole and epinephrine | 700 |
| Actavis/Durata Therapeutics | Merger with Actavis subsidiary | Brings Dalvance a recently approved novel antibiotic for acute skin structure infections | 675 |
| Acorda Therapeutics/Civitas Therapeutics | Company acquisition | Includes CVT 301 in P3 for Parkinson's as well as pulmonary delivery technology | 525 |
| F-star Alpha/BMS | Option to acquire F-star Alpha | Includes FS102 a P1 ready treatment for HER2 positive patients with breast / gastric cancer | 475 |
| CureTech/Medivation | Exclusive global licence | For pidilizumab (CT-011), an immune modulatory anti-PD-1 monoclonal antibody | 335 |
| Forendo Pharma/Apricus Biosciences | Licence [A] | Fispemifene a selective oestrogen modulator in P2 for secondary hypogonadism | 318 |
| Novartis/CSL | Asset purchase | Influenza vaccines | 275 |
| Five Prime/GSK | Expansion of collaboration | Identifying new agents in asthma and COPD | 196 |
| Bavarian Nordic/J&J | Licence and supply | For multivalent MVA-BN Filovirus vaccine | 187 |
| Lexicon Pharmaceuticals/Ipsen | Licence [B] | Telotristat etiprate in P3 for carcinoid syndrome | 145 |
| Brabant Pharma/Zogenix | Acquisition | Includes fenfluramine for orphan I indication of Dravet syndrome | 130 |
| TesoRx Pharma/Aspen | Licence [C] | For TSX 002 an unmodified oral testosterone replacement | 95 |
| Oxford BioMedica/Novartis | Expansion of collaboration | Lentiviral vectors expressing CTL019 CAR-T therapy for leukaemia | 90 |
| Heidelberg Pharma/Roche | Licence with options to targets | Development of ADCs based on coupling α-amantin to antibodies | 66 |
All deals are worldwide unless otherwise noted.
A: US only
B: Outside N America and Japan
C: Excluding US EU Japan, China and the Middle East
Subscribe to our email news alerts
- Senior Medical Copywriter - Highly Awarded Advertising Agency
- £50,000 - £60,000 yearly
- Home Based Account Manager, Medical Communications, UK, Pharma/M...
- Highly competitive salary
- Account Director, Healthcare Marketing Creative Agency, Fixed te...
- Highly competitive salary
- Account Manager, Healthcare Marketing Creative Agency, Fixed ter...
- Highly competitive salary
- Market Access Director, six figure base salary and £5K joining b...
- Highly competitive salary
- Account Manager, 6 month contract, Healthcare Brand communicatio...
- Highly competitive salary
- AbbVie’s Rinvoq receives FDA approval for Crohn’s disease
- Bayer’s Nubeqa combination recommended by NICE to treat metastatic prostate cancer
- AstraZeneca announces positive phase 3 results for Tagrisso combination in lung cancer
- Novo Nordisk announces positive phase 3 results for oral weight-loss drug
- COVID-19: Pfizer’s Paxlovid approved by FDA and Gilead’s Veklury recommended by CHMP
- FDA approves Blueprint Medicines’ Ayvakit for indolent systemic mastocytosis
- Medscape Medical Affairs Selected as Finalist for 2023 Communiqué Awards
- COVID-19: Pfizer’s Paxlovid approved by FDA and Gilead’s Veklury recommended by CHMP
- BMS and Janssen’s antithrombotic granted FDA fast track designation
- Gene therapy, gene editing and perspectives on future use in Parkinson’s disease
- Patient Clinical Trial & Communications Plan Review: A Customer Story
- Shining a Spotlight on Women’s Health Education Outcomes at ACOG 2023
PMHub
Impetus Digital
Impetus Digital has offered virtual advisory boards, clinical trial investigator consortiums, co-author publication working groups, steering committees, and medical education...
